Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lymphoma, T-Cell, Cutaneous

ClinicalTrials.gov lists 633 trials for Lymphoma, T-Cell, Cutaneous or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 66.

MeSH D016410 Neoplasms Neoplasm C04 C15 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 196 Phase 1/2 Phase 1/2 61 Phase 2 Phase 2 174 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 39 Phase 4 Phase 4 10 Not applicable Not applicable 67 Observational Observational 81 Phase 1 Phase 1 196 Phase 1/2 Phase 1/2 61 Phase 2 Phase 2 174 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 39 Phase 4 Phase 4 10 Not applicable Not applicable 67 Observational Observational 81

Trials per phase (log scale)

2 more sections with rows

550 of the 633 trials are tagged with Lymphoma, T-Cell, Cutaneous itself; the rest are tagged with a narrower condition beneath it.

Get the Lymphoma, T-Cell, Cutaneous report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lymphoma, T-Cell, Cutaneous trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 36

1990: 2 trials (Not applicable 1, Phase 2 1) 1991: 1 trials (Phase 2 1) 1992: 1 trials (Phase 2 1) 1993: 1 trials (Phase 2 1) 1994: 3 trials (Phase 2 1, Phase 1 2) 1995: 7 trials (Phase 4 2, Phase 2 2, Phase 1/2 1, Phase 1 2) 1996: 5 trials (Observational 1, Phase 2 1, Phase 1 3) 1997: 8 trials (Not applicable 1, Phase 3 1, Phase 2 3, Phase 1 3) 1998: 15 trials (Not applicable 1, Phase 3 2, Phase 2/3 1, Phase 2 6, Phase 1 5) 1999: 26 trials (Not applicable 3, Phase 3 5, Phase 2 3, Phase 1/2 2, Phase 1 13) 2000: 21 trials (Not applicable 4, Phase 4 1, Phase 3 3, Phase 2 5, Phase 1/2 3, Phase 1 5) 2001: 17 trials (Phase 4 1, Phase 3 1, Phase 2 6, Phase 1/2 2, Phase 1 7) 2002: 20 trials (Observational 1, Not applicable 5, Phase 3 2, Phase 2 1, Phase 1/2 2, Phase 1 9) 2003: 27 trials (Observational 1, Not applicable 6, Phase 3 2, Phase 2/3 1, Phase 2 6, Phase 1/2 6, Phase 1 5) 2004: 26 trials (Observational 4, Not applicable 4, Phase 4 1, Phase 2 6, Phase 1/2 1, Phase 1 10) 2005: 34 trials (Observational 4, Not applicable 3, Phase 3 2, Phase 2 17, Phase 1/2 4, Phase 1 4) 2006: 24 trials (Observational 3, Not applicable 3, Phase 3 2, Phase 2 5, Phase 1/2 3, Phase 1 8) 2007: 36 trials (Observational 4, Not applicable 3, Phase 3 3, Phase 2 13, Phase 1/2 2, Phase 1 11) 2008: 31 trials (Observational 9, Not applicable 2, Phase 3 3, Phase 2 7, Phase 1/2 3, Phase 1 7) 2009: 21 trials (Other 1, Observational 5, Not applicable 3, Phase 3 1, Phase 2 4, Phase 1/2 2, Phase 1 5) 2010: 29 trials (Observational 4, Not applicable 4, Phase 4 1, Phase 3 1, Phase 2 8, Phase 1/2 3, Phase 1 8) 2011: 18 trials (Observational 2, Not applicable 1, Phase 2 8, Phase 1/2 2, Phase 1 5) 2012: 19 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 3 2, Phase 2 5, Phase 1/2 1, Phase 1 7) 2013: 13 trials (Not applicable 1, Phase 3 2, Phase 2 1, Phase 1/2 4, Phase 1 5) 2014: 12 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 2 4, Phase 1 5) 2015: 15 trials (Observational 3, Not applicable 2, Phase 3 1, Phase 2 4, Phase 1 5) 2016: 19 trials (Observational 6, Not applicable 1, Phase 2 3, Phase 1/2 1, Phase 1 8) 2017: 18 trials (Not applicable 2, Phase 3 2, Phase 2 5, Phase 1/2 4, Phase 1 5) 2018: 14 trials (Phase 2 7, Phase 1 7) 2019: 18 trials (Observational 4, Not applicable 2, Phase 2 6, Phase 1/2 1, Phase 1 5) 2020: 11 trials (Not applicable 2, Phase 2 4, Phase 1/2 1, Phase 1 4) 2021: 15 trials (Observational 4, Not applicable 1, Phase 2 3, Phase 1/2 3, Phase 1 4) 2022: 18 trials (Observational 5, Not applicable 2, Phase 3 1, Phase 2 4, Phase 1 6) 2023: 22 trials (Observational 6, Not applicable 2, Phase 4 1, Phase 2 6, Phase 1/2 2, Phase 1 5) 2024: 17 trials (Observational 6, Phase 2 4, Phase 1/2 2, Phase 1 5) 2025: 20 trials (Observational 5, Not applicable 2, Phase 3 2, Phase 2 3, Phase 1/2 3, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 15
2025 20
2024 17
2023 22
2022 18
2021 15
2020 11
2019 18
2018 14
2017 18

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 18 trials starting in 2026 and about 20 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 38 trials still running at the 2026-10-09 snapshot; registered median of 43 months across 435 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lymphoma, T-Cell, Cutaneous trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 196
Phase 1/2 61
Phase 2 174
Phase 2/3 2
Phase 3 39
Phase 4 10
Not applicable 67
Observational 81
Expanded access 2
Unknown 1

How many Lymphoma, T-Cell, Cutaneous trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 20
Recruiting 54
Enrolling by invitation 1
Active, not recruiting 21
Completed 346

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lymphoma, T-Cell, Cutaneous trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 66
European Organisation for Research and Treatment of Cancer - EORTC 14
National Institutes of Health Clinical Center (CC) 12

Which drugs are being tested for Lymphoma, T-Cell, Cutaneous? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 45
Busulfan 26
Romidepsin 19

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 48
Peripheral blood stem cell transplantation 44
Mofetil Mycophenolate 32
Cyclosporine 0.05% 30
Allogeneic (Allo) hematopoietic stem cell transplantation 29

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lymphoma, T-Cell, Cutaneous trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Sepsis 116 36
Pneumonia 108 32
Platelet count decreased 99 13
Febrile neutropenia 95 20
1 yr TRM 93 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Lymphoma, T-Cell, Cutaneous? (109)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway. Investigational new drugs 2025 Yes
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025 Yes
Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma. Blood advances 2025 Yes
Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025 Yes
Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma: A Nonrandomized Clinical Trial. JAMA dermatology 2025 Yes

Showing 5 of 109 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (48)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Primary cutaneous T-cell lymphoma Annual incidence 1-9 / 1 000 000 United Kingdom GB Exact
Primary cutaneous T-cell lymphoma Annual incidence 1-9 / 1 000 000 United Kingdom GB Exact
Primary cutaneous T-cell lymphoma Annual incidence 1-9 / 1 000 000 Austria Not stated Exact
Primary cutaneous T-cell lymphoma Annual incidence 1-9 / 1 000 000 Netherlands Not stated Exact
Primary cutaneous T-cell lymphoma Annual incidence 1-9 / 1 000 000 Bulgaria Not stated Exact

Showing 5 of 48 prevalence observations.

Start your 14-day trial Email me all 48 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Primary cutaneous T-cell lymphoma 171901 Exact Orphadata Science knowledge files, Product 1
Primary cutaneous T-cell lymphoma 171901 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages